MIB AGENTS

OutSmarting OSTEOSARCOMA

Funding Meaningful Osteosarcoma Research Together

Since 2017, the OutSmarting Osteosarcoma annual research grant program has supported 18 investigators and awarded $1,550,000 to support osteosarcoma research.

Career Development Support

$50,000 grant over one year to support young investigators studying osteosarcoma

Focus on Late Stage Translational Studies

$100,000 grant over one year to any investigator with a study that will focus on late-stage translational studies

Partners Collaborating for a Cure

Partners with foundations focused on fundraising for osteosarcoma or pediatric cancer research, but do not have a research grant program

Robust Review Process

Our two tier-review process consists of independent peer review and stakeholder review that uniquely incorporates patient and family perspective

Family Funds Supporting Science

Collaboration among the scientific and patient community is a key hallmark of MIB Agents

OUTSMARTING BY THE NUMBERS

18
investigators and studies supported

$1,550,000
awarded since 2017

8
funding collaborations

OutSmarting Osteosarcoma Research has led to:

10
publications shared in public domain

7
clinical trials

$11.5 million
secured in funding



78
presentations shared with the scientific community

MiB AGENTS

OutSmarting OSTEOSARCOMA

Funding Meaningful Osteosarcoma Research Together

GRANT Recipients

2023

Robert J. Canter, MD University of California, Davis
Inhaled canine IL-15 to maximize immunotherapy responses in dogs with metastatic osteosarcoma.

Ryan D. Roberts, MD, PhD The Abigail Wexner Research Institute at Nationwide Children's Hospital
Combination therapies targeting heterogeneity and lung environment in metastatic osteosarcoma.

Shahab Asgharzadeh, MD Children's Hospital Los Angeles
will study the Identification of circulating immune signature as a biomarker of disease response and resistance in patients with relapsed osteosarcoma treated with nivolumab and regorafenib.

Sam Volchenboum, MD, PhD University of Chicago
Data commons to support new treatments for osteosarcoma.

Heather Gardner, DVM, PhD, DACVIM (Oncology) Tufts University
Liquid biopsy platforms to support early detection of metastasis and inform future interventions in osteosarcoma.

2022

Amanda Marinoff, MD University of California, San Francisco
Novel molecular biomarkers for risk stratification in pediatric osteosarcoma.

Michael Leibowitz, MD, PhD University of Colorado/Children's Hospital Colorado
Altering the tumor microenvironment to increase epitope spreading and augment chimeric antigen receptor T cell therapy for metastatic osteosarcoma.

Marta Roman Moreno, PhD University of California, San Francisco
CRISPRi screening to identify vulnerabilities in metastatic osteosarcoma.

Dan Regan, DVM, PhD Colorado State University
Focal Adhesion Kinase (FAK) inhibition to improve losartan-sunitinib immunotherapy in metastatic osteosarcoma.

Jason Yustein, MD, PhD Emory University
Combinatorial therapies to improve immune-mediated approaches for osteosarcoma.

Eunice Lopez-Fuentes, PhD University of California, San Francisco
Two epigenetically distinct cellular states in osteosarcoma, defined by a cluster-specific set of pioneer transcription factors and show differential drug response.

2022

Kristen VanHeyst, DO UH Rainbow Babies and Children's Hospital
Modulating TGF-beta Signaling in the tumor microenvironment as an effective therapy for osteosarcoma.

2021

Kurt Weiss, MD University of Pittsburgh School of Medicine
Exploring Aldehyde Dehydrogenase and Androgen Receptor Actions to OutSmart Osteosarcoma Metastases.

2020

J. Andrew Livingston, MD University of Texas MD Anderson Cancer Center
Defining the Immune Atlas in Osteosarcoma Lung Metastases.

2019

Alex Y. Huang, MD, PhD Case Western Reserve University / Angie Fowler AYA Cancer Institute Initiative
New Immune-mediated Therapies for Lung OS.

2018

Matteo Trucco, MD Cleveland Clinic
Clinical trial of disulfiram to overcome chemotherapy resistance in sarcomas.

2017

Joshua Schiffman, MD University of Utah
EP53 Nanoparticle Development